Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report)'s stock price reached a new 52-week high on Friday . The stock traded as high as C$3.50 and last traded at C$3.45, with a volume of 45900 shares. The stock had previously closed at C$3.45.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a report on Monday, September 30th. Raymond James upgraded shares of Medexus Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price target for the company from C$3.00 to C$4.00 in a research note on Wednesday, November 20th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, December 23rd. Three research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Medexus Pharmaceuticals has a consensus rating of "Strong Buy" and an average target price of C$5.25.
View Our Latest Stock Analysis on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
The firm has a fifty day simple moving average of C$2.68 and a 200-day simple moving average of C$2.47. The firm has a market cap of C$83.89 million, a price-to-earnings ratio of 68.40 and a beta of 1.96.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
